GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | MCL1 | decreases expression | EXP | | 6480464 | CTD | resveratrol results in decreased expression of MCL1 protein | PMID:12902349 PMID:14749477 PMID:18347188 PMID:23251493 PMID:23372833 PMID:24090995 PMID:24331535 PMID:25408576 | MCL1 | increases degradation | EXP | | 6480464 | CTD | resveratrol results in increased degradation of MCL1 protein | PMID:22245142 | MCL1 | multiple interactions | EXP | | 6480464 | CTD | [clofarabine co-treated with resveratrol] inhibits the reaction [BCL2L1 mutant form results in increased expression of MCL1 protein]; [resveratrol co-treated with clofarabine co-treated with Cycloheximide] results in decreased expression of MCL1 protein; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]; [resveratrol co-treated with clofarabine] results in decreased expression of MCL1 protein; [resveratrol co-treated with clofarabine] results in increased expression of MCL1 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[resveratrol co-treated with clofarabine] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [clofarabine promotes the reaction [resveratrol results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol promotes the reaction [clofarabine results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[resveratrol co-treated with clofarabine] results in increased expression of MCL1 protein]; clofarabine promotes the reaction [resveratrol results in decreased expression of MCL1 protein]; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of CASP3 protein]; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of PARP1 protein]; resveratrol inhibits the reaction [STAT3 protein results in increased expression of MCL1 protein]; resveratrol promotes the reaction [clofarabine results in decreased expression of MCL1 protein]; resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of MCL1 protein] | PMID:16546976 PMID:24924397 PMID:25408576 PMID:25895606 | MCL1 | increases expression | ISO | Mcl1 (Mus musculus) | 6480464 | CTD | resveratrol results in increased expression of MCL1 mRNA | PMID:16081268 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |